nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—CYP1A2—Carmustine—lymphatic system cancer	0.194	0.334	CbGbCtD
Pomalidomide—ABCB1—Mitoxantrone—lymphatic system cancer	0.0799	0.137	CbGbCtD
Pomalidomide—CYP3A4—Cytarabine—lymphatic system cancer	0.0695	0.12	CbGbCtD
Pomalidomide—CYP3A4—Teniposide—lymphatic system cancer	0.0685	0.118	CbGbCtD
Pomalidomide—ABCB1—Vincristine—lymphatic system cancer	0.055	0.0946	CbGbCtD
Pomalidomide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0479	0.0823	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—lymphatic system cancer	0.0333	0.0573	CbGbCtD
Pomalidomide—CYP3A4—Vincristine—lymphatic system cancer	0.033	0.0567	CbGbCtD
Pomalidomide—Pancytopenia—Bleomycin—lymphatic system cancer	0.00148	0.00353	CcSEcCtD
Pomalidomide—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.00147	0.00351	CcSEcCtD
Pomalidomide—Hypokalaemia—Carmustine—lymphatic system cancer	0.00143	0.00342	CcSEcCtD
Pomalidomide—Urinary retention—Vincristine—lymphatic system cancer	0.00143	0.00341	CcSEcCtD
Pomalidomide—Interstitial lung disease—Methotrexate—lymphatic system cancer	0.00142	0.00339	CcSEcCtD
Pomalidomide—Weight decreased—Bleomycin—lymphatic system cancer	0.00141	0.00337	CcSEcCtD
Pomalidomide—Pneumonia—Bleomycin—lymphatic system cancer	0.0014	0.00334	CcSEcCtD
Pomalidomide—Dehydration—Vincristine—lymphatic system cancer	0.00139	0.00333	CcSEcCtD
Pomalidomide—Muscular weakness—Carmustine—lymphatic system cancer	0.00139	0.00331	CcSEcCtD
Pomalidomide—Confusional state—Teniposide—lymphatic system cancer	0.00138	0.00331	CcSEcCtD
Pomalidomide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00137	0.00328	CcSEcCtD
Pomalidomide—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00137	0.00327	CcSEcCtD
Pomalidomide—Anaemia—Fludarabine—lymphatic system cancer	0.00137	0.00327	CcSEcCtD
Pomalidomide—Infection—Teniposide—lymphatic system cancer	0.00136	0.00326	CcSEcCtD
Pomalidomide—Dehydration—Mitoxantrone—lymphatic system cancer	0.00136	0.00325	CcSEcCtD
Pomalidomide—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00134	0.00321	CcSEcCtD
Pomalidomide—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00133	0.00318	CcSEcCtD
Pomalidomide—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00133	0.00317	CcSEcCtD
Pomalidomide—Leukopenia—Fludarabine—lymphatic system cancer	0.00132	0.00316	CcSEcCtD
Pomalidomide—Muscular weakness—Vincristine—lymphatic system cancer	0.00132	0.00316	CcSEcCtD
Pomalidomide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00132	0.00315	CcSEcCtD
Pomalidomide—Cough—Fludarabine—lymphatic system cancer	0.00129	0.00308	CcSEcCtD
Pomalidomide—Pancytopenia—Carmustine—lymphatic system cancer	0.00129	0.00308	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00129	0.00308	CcSEcCtD
Pomalidomide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00127	0.00305	CcSEcCtD
Pomalidomide—Neutropenia—Carmustine—lymphatic system cancer	0.00127	0.00304	CcSEcCtD
Pomalidomide—Arthralgia—Fludarabine—lymphatic system cancer	0.00126	0.00301	CcSEcCtD
Pomalidomide—Pancytopenia—Vincristine—lymphatic system cancer	0.00123	0.00294	CcSEcCtD
Pomalidomide—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00123	0.00293	CcSEcCtD
Pomalidomide—Dyspnoea—Teniposide—lymphatic system cancer	0.00122	0.00293	CcSEcCtD
Pomalidomide—Pneumonia—Carmustine—lymphatic system cancer	0.00122	0.00291	CcSEcCtD
Pomalidomide—Confusional state—Fludarabine—lymphatic system cancer	0.00122	0.00291	CcSEcCtD
Pomalidomide—Neutropenia—Vincristine—lymphatic system cancer	0.00121	0.0029	CcSEcCtD
Pomalidomide—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.0012	0.00287	CcSEcCtD
Pomalidomide—Infection—Fludarabine—lymphatic system cancer	0.0012	0.00287	CcSEcCtD
Pomalidomide—Decreased appetite—Teniposide—lymphatic system cancer	0.00119	0.00285	CcSEcCtD
Pomalidomide—Renal failure—Carmustine—lymphatic system cancer	0.00119	0.00285	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00119	0.00284	CcSEcCtD
Pomalidomide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00118	0.00283	CcSEcCtD
Pomalidomide—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00118	0.00283	CcSEcCtD
Pomalidomide—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00118	0.00282	CcSEcCtD
Pomalidomide—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00118	0.00282	CcSEcCtD
Pomalidomide—Urinary tract infection—Carmustine—lymphatic system cancer	0.00118	0.00281	CcSEcCtD
Pomalidomide—Rash—Mechlorethamine—lymphatic system cancer	0.00117	0.00281	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00117	0.00281	CcSEcCtD
Pomalidomide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00117	0.0028	CcSEcCtD
Pomalidomide—Weight decreased—Vincristine—lymphatic system cancer	0.00117	0.0028	CcSEcCtD
Pomalidomide—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00117	0.00279	CcSEcCtD
Pomalidomide—Pneumonia—Vincristine—lymphatic system cancer	0.00116	0.00278	CcSEcCtD
Pomalidomide—Weight increased—Mitoxantrone—lymphatic system cancer	0.00115	0.00275	CcSEcCtD
Pomalidomide—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00114	0.00273	CcSEcCtD
Pomalidomide—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00114	0.00272	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00113	0.00271	CcSEcCtD
Pomalidomide—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00113	0.00271	CcSEcCtD
Pomalidomide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00113	0.0027	CcSEcCtD
Pomalidomide—Chills—Bleomycin—lymphatic system cancer	0.00112	0.00267	CcSEcCtD
Pomalidomide—Renal failure—Mitoxantrone—lymphatic system cancer	0.00111	0.00265	CcSEcCtD
Pomalidomide—Nausea—Mechlorethamine—lymphatic system cancer	0.00111	0.00264	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.0011	0.00264	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.0011	0.00263	CcSEcCtD
Pomalidomide—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00109	0.00262	CcSEcCtD
Pomalidomide—Body temperature increased—Teniposide—lymphatic system cancer	0.00109	0.00259	CcSEcCtD
Pomalidomide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00108	0.00257	CcSEcCtD
Pomalidomide—Oedema peripheral—Carmustine—lymphatic system cancer	0.00107	0.00256	CcSEcCtD
Pomalidomide—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00107	0.00255	CcSEcCtD
Pomalidomide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00105	0.00251	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00104	0.00249	CcSEcCtD
Pomalidomide—Fatigue—Fludarabine—lymphatic system cancer	0.00104	0.00249	CcSEcCtD
Pomalidomide—Pain—Fludarabine—lymphatic system cancer	0.00103	0.00247	CcSEcCtD
Pomalidomide—Constipation—Fludarabine—lymphatic system cancer	0.00103	0.00247	CcSEcCtD
Pomalidomide—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00102	0.00245	CcSEcCtD
Pomalidomide—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00102	0.00244	CcSEcCtD
Pomalidomide—Urethral disorder—Vincristine—lymphatic system cancer	0.00102	0.00243	CcSEcCtD
Pomalidomide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00101	0.00242	CcSEcCtD
Pomalidomide—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.001	0.0024	CcSEcCtD
Pomalidomide—Anaemia—Bleomycin—lymphatic system cancer	0.001	0.0024	CcSEcCtD
Pomalidomide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000994	0.00238	CcSEcCtD
Pomalidomide—Asthenia—Teniposide—lymphatic system cancer	0.000985	0.00236	CcSEcCtD
Pomalidomide—Pruritus—Teniposide—lymphatic system cancer	0.000971	0.00232	CcSEcCtD
Pomalidomide—Leukopenia—Bleomycin—lymphatic system cancer	0.00097	0.00232	CcSEcCtD
Pomalidomide—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000968	0.00231	CcSEcCtD
Pomalidomide—Cardiac disorder—Vincristine—lymphatic system cancer	0.000963	0.0023	CcSEcCtD
Pomalidomide—Body temperature increased—Fludarabine—lymphatic system cancer	0.000954	0.00228	CcSEcCtD
Pomalidomide—Mental disorder—Carmustine—lymphatic system cancer	0.000952	0.00228	CcSEcCtD
Pomalidomide—Malnutrition—Carmustine—lymphatic system cancer	0.000946	0.00226	CcSEcCtD
Pomalidomide—Cough—Bleomycin—lymphatic system cancer	0.000946	0.00226	CcSEcCtD
Pomalidomide—Angiopathy—Vincristine—lymphatic system cancer	0.000941	0.00225	CcSEcCtD
Pomalidomide—Diarrhoea—Teniposide—lymphatic system cancer	0.000939	0.00225	CcSEcCtD
Pomalidomide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000935	0.00224	CcSEcCtD
Pomalidomide—Back pain—Carmustine—lymphatic system cancer	0.000915	0.00219	CcSEcCtD
Pomalidomide—Mental disorder—Vincristine—lymphatic system cancer	0.000909	0.00217	CcSEcCtD
Pomalidomide—Chills—Mitoxantrone—lymphatic system cancer	0.000907	0.00217	CcSEcCtD
Pomalidomide—Confusional state—Bleomycin—lymphatic system cancer	0.000892	0.00213	CcSEcCtD
Pomalidomide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000889	0.00213	CcSEcCtD
Pomalidomide—Tremor—Carmustine—lymphatic system cancer	0.000887	0.00212	CcSEcCtD
Pomalidomide—Infection—Bleomycin—lymphatic system cancer	0.000879	0.0021	CcSEcCtD
Pomalidomide—Anaemia—Carmustine—lymphatic system cancer	0.000875	0.00209	CcSEcCtD
Pomalidomide—Back pain—Vincristine—lymphatic system cancer	0.000874	0.00209	CcSEcCtD
Pomalidomide—Vomiting—Teniposide—lymphatic system cancer	0.000873	0.00209	CcSEcCtD
Pomalidomide—Sepsis—Methotrexate—lymphatic system cancer	0.00087	0.00208	CcSEcCtD
Pomalidomide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000866	0.00207	CcSEcCtD
Pomalidomide—Asthenia—Fludarabine—lymphatic system cancer	0.000866	0.00207	CcSEcCtD
Pomalidomide—Rash—Teniposide—lymphatic system cancer	0.000866	0.00207	CcSEcCtD
Pomalidomide—Dermatitis—Teniposide—lymphatic system cancer	0.000865	0.00207	CcSEcCtD
Pomalidomide—Headache—Teniposide—lymphatic system cancer	0.00086	0.00206	CcSEcCtD
Pomalidomide—Pruritus—Fludarabine—lymphatic system cancer	0.000854	0.00204	CcSEcCtD
Pomalidomide—Back pain—Mitoxantrone—lymphatic system cancer	0.000851	0.00203	CcSEcCtD
Pomalidomide—Leukopenia—Carmustine—lymphatic system cancer	0.000847	0.00202	CcSEcCtD
Pomalidomide—Anaemia—Vincristine—lymphatic system cancer	0.000835	0.002	CcSEcCtD
Pomalidomide—Diarrhoea—Fludarabine—lymphatic system cancer	0.000826	0.00197	CcSEcCtD
Pomalidomide—Nausea—Teniposide—lymphatic system cancer	0.000816	0.00195	CcSEcCtD
Pomalidomide—Anaemia—Mitoxantrone—lymphatic system cancer	0.000813	0.00194	CcSEcCtD
Pomalidomide—Vertigo—Vincristine—lymphatic system cancer	0.000812	0.00194	CcSEcCtD
Pomalidomide—Leukopenia—Vincristine—lymphatic system cancer	0.000809	0.00193	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000806	0.00193	CcSEcCtD
Pomalidomide—Anxiety—Carmustine—lymphatic system cancer	0.000803	0.00192	CcSEcCtD
Pomalidomide—Dyspnoea—Bleomycin—lymphatic system cancer	0.000789	0.00189	CcSEcCtD
Pomalidomide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000787	0.00188	CcSEcCtD
Pomalidomide—Confusional state—Carmustine—lymphatic system cancer	0.000779	0.00186	CcSEcCtD
Pomalidomide—Decreased appetite—Bleomycin—lymphatic system cancer	0.000769	0.00184	CcSEcCtD
Pomalidomide—Cough—Mitoxantrone—lymphatic system cancer	0.000768	0.00184	CcSEcCtD
Pomalidomide—Infection—Carmustine—lymphatic system cancer	0.000767	0.00183	CcSEcCtD
Pomalidomide—Vomiting—Fludarabine—lymphatic system cancer	0.000767	0.00183	CcSEcCtD
Pomalidomide—Rash—Fludarabine—lymphatic system cancer	0.000761	0.00182	CcSEcCtD
Pomalidomide—Dermatitis—Fludarabine—lymphatic system cancer	0.00076	0.00182	CcSEcCtD
Pomalidomide—Pain—Bleomycin—lymphatic system cancer	0.000757	0.00181	CcSEcCtD
Pomalidomide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000756	0.00181	CcSEcCtD
Pomalidomide—Headache—Fludarabine—lymphatic system cancer	0.000756	0.00181	CcSEcCtD
Pomalidomide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000749	0.00179	CcSEcCtD
Pomalidomide—Anxiety—Mitoxantrone—lymphatic system cancer	0.000746	0.00178	CcSEcCtD
Pomalidomide—Infection—Vincristine—lymphatic system cancer	0.000732	0.00175	CcSEcCtD
Pomalidomide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000729	0.00174	CcSEcCtD
Pomalidomide—Confusional state—Mitoxantrone—lymphatic system cancer	0.000724	0.00173	CcSEcCtD
Pomalidomide—Nervous system disorder—Vincristine—lymphatic system cancer	0.000723	0.00173	CcSEcCtD
Pomalidomide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000722	0.00173	CcSEcCtD
Pomalidomide—Nausea—Fludarabine—lymphatic system cancer	0.000717	0.00171	CcSEcCtD
Pomalidomide—Infection—Mitoxantrone—lymphatic system cancer	0.000713	0.00171	CcSEcCtD
Pomalidomide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000713	0.0017	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000704	0.00168	CcSEcCtD
Pomalidomide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000703	0.00168	CcSEcCtD
Pomalidomide—Body temperature increased—Bleomycin—lymphatic system cancer	0.000699	0.00167	CcSEcCtD
Pomalidomide—Insomnia—Carmustine—lymphatic system cancer	0.000699	0.00167	CcSEcCtD
Pomalidomide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000697	0.00167	CcSEcCtD
Pomalidomide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000694	0.00166	CcSEcCtD
Pomalidomide—Dyspnoea—Carmustine—lymphatic system cancer	0.000689	0.00165	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000672	0.00161	CcSEcCtD
Pomalidomide—Decreased appetite—Carmustine—lymphatic system cancer	0.000671	0.0016	CcSEcCtD
Pomalidomide—Insomnia—Vincristine—lymphatic system cancer	0.000667	0.00159	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000667	0.00159	CcSEcCtD
Pomalidomide—Constipation—Carmustine—lymphatic system cancer	0.00066	0.00158	CcSEcCtD
Pomalidomide—Pain—Carmustine—lymphatic system cancer	0.00066	0.00158	CcSEcCtD
Pomalidomide—Breast disorder—Methotrexate—lymphatic system cancer	0.000658	0.00157	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000654	0.00156	CcSEcCtD
Pomalidomide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000652	0.00156	CcSEcCtD
Pomalidomide—Decreased appetite—Vincristine—lymphatic system cancer	0.000641	0.00153	CcSEcCtD
Pomalidomide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00064	0.00153	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000636	0.00152	CcSEcCtD
Pomalidomide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000636	0.00152	CcSEcCtD
Pomalidomide—Fatigue—Vincristine—lymphatic system cancer	0.000636	0.00152	CcSEcCtD
Pomalidomide—Asthenia—Bleomycin—lymphatic system cancer	0.000635	0.00152	CcSEcCtD
Pomalidomide—Pain—Vincristine—lymphatic system cancer	0.00063	0.00151	CcSEcCtD
Pomalidomide—Constipation—Vincristine—lymphatic system cancer	0.00063	0.00151	CcSEcCtD
Pomalidomide—Pruritus—Bleomycin—lymphatic system cancer	0.000626	0.0015	CcSEcCtD
Pomalidomide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000624	0.00149	CcSEcCtD
Pomalidomide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000619	0.00148	CcSEcCtD
Pomalidomide—Pain—Mitoxantrone—lymphatic system cancer	0.000614	0.00147	CcSEcCtD
Pomalidomide—Constipation—Mitoxantrone—lymphatic system cancer	0.000614	0.00147	CcSEcCtD
Pomalidomide—Body temperature increased—Carmustine—lymphatic system cancer	0.000611	0.00146	CcSEcCtD
Pomalidomide—Pancytopenia—Methotrexate—lymphatic system cancer	0.000597	0.00143	CcSEcCtD
Pomalidomide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000592	0.00141	CcSEcCtD
Pomalidomide—Neutropenia—Methotrexate—lymphatic system cancer	0.000588	0.00141	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000585	0.0014	CcSEcCtD
Pomalidomide—Body temperature increased—Vincristine—lymphatic system cancer	0.000583	0.00139	CcSEcCtD
Pomalidomide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000569	0.00136	CcSEcCtD
Pomalidomide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000568	0.00136	CcSEcCtD
Pomalidomide—Pneumonia—Methotrexate—lymphatic system cancer	0.000564	0.00135	CcSEcCtD
Pomalidomide—Vomiting—Bleomycin—lymphatic system cancer	0.000563	0.00134	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—lymphatic system cancer	0.000561	0.00134	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—lymphatic system cancer	0.000561	0.00134	CcSEcCtD
Pomalidomide—Rash—Bleomycin—lymphatic system cancer	0.000558	0.00133	CcSEcCtD
Pomalidomide—Dermatitis—Bleomycin—lymphatic system cancer	0.000557	0.00133	CcSEcCtD
Pomalidomide—Asthenia—Carmustine—lymphatic system cancer	0.000554	0.00132	CcSEcCtD
Pomalidomide—Renal failure—Methotrexate—lymphatic system cancer	0.000551	0.00132	CcSEcCtD
Pomalidomide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000543	0.0013	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00053	0.00127	CcSEcCtD
Pomalidomide—Epistaxis—Methotrexate—lymphatic system cancer	0.000529	0.00126	CcSEcCtD
Pomalidomide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000529	0.00126	CcSEcCtD
Pomalidomide—Asthenia—Vincristine—lymphatic system cancer	0.000529	0.00126	CcSEcCtD
Pomalidomide—Diarrhoea—Carmustine—lymphatic system cancer	0.000528	0.00126	CcSEcCtD
Pomalidomide—Nausea—Bleomycin—lymphatic system cancer	0.000526	0.00126	CcSEcCtD
Pomalidomide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000515	0.00123	CcSEcCtD
Pomalidomide—Dizziness—Carmustine—lymphatic system cancer	0.000511	0.00122	CcSEcCtD
Pomalidomide—Diarrhoea—Vincristine—lymphatic system cancer	0.000504	0.00121	CcSEcCtD
Pomalidomide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000497	0.00119	CcSEcCtD
Pomalidomide—Urethral disorder—Methotrexate—lymphatic system cancer	0.000494	0.00118	CcSEcCtD
Pomalidomide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000491	0.00117	CcSEcCtD
Pomalidomide—Vomiting—Carmustine—lymphatic system cancer	0.000491	0.00117	CcSEcCtD
Pomalidomide—Dizziness—Vincristine—lymphatic system cancer	0.000488	0.00117	CcSEcCtD
Pomalidomide—Rash—Carmustine—lymphatic system cancer	0.000487	0.00116	CcSEcCtD
Pomalidomide—Dermatitis—Carmustine—lymphatic system cancer	0.000487	0.00116	CcSEcCtD
Pomalidomide—Headache—Carmustine—lymphatic system cancer	0.000484	0.00116	CcSEcCtD
Pomalidomide—Vomiting—Vincristine—lymphatic system cancer	0.000469	0.00112	CcSEcCtD
Pomalidomide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000467	0.00112	CcSEcCtD
Pomalidomide—Rash—Vincristine—lymphatic system cancer	0.000465	0.00111	CcSEcCtD
Pomalidomide—Dermatitis—Vincristine—lymphatic system cancer	0.000464	0.00111	CcSEcCtD
Pomalidomide—Headache—Vincristine—lymphatic system cancer	0.000462	0.0011	CcSEcCtD
Pomalidomide—Nausea—Carmustine—lymphatic system cancer	0.000459	0.0011	CcSEcCtD
Pomalidomide—Angiopathy—Methotrexate—lymphatic system cancer	0.000457	0.00109	CcSEcCtD
Pomalidomide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000457	0.00109	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000454	0.00108	CcSEcCtD
Pomalidomide—Rash—Mitoxantrone—lymphatic system cancer	0.000453	0.00108	CcSEcCtD
Pomalidomide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000452	0.00108	CcSEcCtD
Pomalidomide—Chills—Methotrexate—lymphatic system cancer	0.000452	0.00108	CcSEcCtD
Pomalidomide—Headache—Mitoxantrone—lymphatic system cancer	0.00045	0.00108	CcSEcCtD
Pomalidomide—Mental disorder—Methotrexate—lymphatic system cancer	0.000441	0.00105	CcSEcCtD
Pomalidomide—Malnutrition—Methotrexate—lymphatic system cancer	0.000438	0.00105	CcSEcCtD
Pomalidomide—Nausea—Vincristine—lymphatic system cancer	0.000438	0.00105	CcSEcCtD
Pomalidomide—Nausea—Mitoxantrone—lymphatic system cancer	0.000426	0.00102	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—lymphatic system cancer	0.000424	0.00101	CcSEcCtD
Pomalidomide—Anaemia—Methotrexate—lymphatic system cancer	0.000405	0.000968	CcSEcCtD
Pomalidomide—Vertigo—Methotrexate—lymphatic system cancer	0.000394	0.000941	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—lymphatic system cancer	0.000392	0.000938	CcSEcCtD
Pomalidomide—Cough—Methotrexate—lymphatic system cancer	0.000382	0.000914	CcSEcCtD
Pomalidomide—Arthralgia—Methotrexate—lymphatic system cancer	0.000373	0.000892	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000371	0.000886	CcSEcCtD
Pomalidomide—Confusional state—Methotrexate—lymphatic system cancer	0.000361	0.000862	CcSEcCtD
Pomalidomide—Infection—Methotrexate—lymphatic system cancer	0.000355	0.00085	CcSEcCtD
Pomalidomide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000351	0.000839	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00035	0.000837	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—lymphatic system cancer	0.000347	0.000831	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000346	0.000827	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000326	0.000779	CcSEcCtD
Pomalidomide—Insomnia—Methotrexate—lymphatic system cancer	0.000324	0.000773	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000319	0.000762	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000311	0.000743	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000309	0.000738	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—lymphatic system cancer	0.000308	0.000737	CcSEcCtD
Pomalidomide—Pain—Methotrexate—lymphatic system cancer	0.000306	0.000731	CcSEcCtD
Pomalidomide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000295	0.000705	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000283	0.000676	CcSEcCtD
Pomalidomide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000264	0.00063	CcSEcCtD
Pomalidomide—Asthenia—Methotrexate—lymphatic system cancer	0.000257	0.000614	CcSEcCtD
Pomalidomide—Pruritus—Methotrexate—lymphatic system cancer	0.000253	0.000605	CcSEcCtD
Pomalidomide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000245	0.000585	CcSEcCtD
Pomalidomide—Dizziness—Methotrexate—lymphatic system cancer	0.000237	0.000566	CcSEcCtD
Pomalidomide—Vomiting—Methotrexate—lymphatic system cancer	0.000227	0.000544	CcSEcCtD
Pomalidomide—Rash—Methotrexate—lymphatic system cancer	0.000226	0.000539	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—lymphatic system cancer	0.000225	0.000539	CcSEcCtD
Pomalidomide—Headache—Methotrexate—lymphatic system cancer	0.000224	0.000536	CcSEcCtD
Pomalidomide—Nausea—Methotrexate—lymphatic system cancer	0.000212	0.000508	CcSEcCtD
